Business Wire·May 12, 2026, 1:00 AM ET

Number of Shares and Voting Rights of Innate Pharma as of April 16, 2026

Innate Pharma SA disclosed its total shares outstanding & voting rights as of April 16, 2026, pursuant to French Commercial Code & AMF regulations.
The total number of shares outstanding is 93,934,210, comprising 93,921,863 ordinary shares, 4,766 Preferred Shares 2016, & 7,581 Preferred Shares 2017.
The total number of theoretical voting rights is 93,921,863, calculated including all shares with attached voting rights.
The total number of exercisable voting rights is 93,903,288, excluding treasury shares held by the company.
Innate Pharma is a global clinical-stage biotechnology company developing immunotherapies for cancer patients.
The company's portfolio includes IPH4502 for solid tumors, lacutamab for lymphomas, & monalizumab for non-small cell lung cancer in collaboration with AstraZeneca.
Innate Pharma maintains collaborations with Sanofi & AstraZeneca & is headquartered in Marseille, France, with a US office in Rockville, MD.
The company is listed on Euronext Paris under ticker IPH & on Nasdaq under ticker IPHA.